• Latest Posts

While working on its HIV Cure, Gilead gives Europe an ‘HIV Vaccine’

Gilead licenses Danish Bispecific antibodies for the next HIV Cure

How could the HIV Field benefit from Gilead’s new €2M Research Grants?

After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie

Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal

A Group of French Medics are Questioning the Fastest-Growing Big Biotech in the World…


After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Gilead acquired epigenetics-expert EpiTherapeutics

Phenex sells out its main programme to Gilead

How Gilead’s Hepatitis C Treatment challenges European Public Health Systems